Investment analysts at StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the medical device company’s stock.
NeuroMetrix Price Performance
Shares of NASDAQ:NURO opened at $3.90 on Friday. The company has a market capitalization of $7.97 million, a P/E ratio of -0.85 and a beta of 2.18. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73. The stock’s fifty day simple moving average is $4.06 and its 200-day simple moving average is $3.84.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last released its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. The firm had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same quarter last year, the business posted ($1.66) EPS.
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
Recommended Stories
- Five stocks we like better than NeuroMetrix
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- Golden Cross Stocks: Pattern, Examples and Charts
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- How to Capture the Benefits of Dividend Increases
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.